Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | DRD3 | P35462 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | PDE6D | O43924 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.33 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7476278 | 0.94 | CXCR4 (0.39) | MAPTL3MBTL1HPGDKDM4ECXCR4 | |
| SCHEMBL17223973 | 0.92 | CXCR4 (0.38) | MAPTL3MBTL1HPGDKDM4ECXCR4 | |
| SCHEMBL15871097 | 0.92 | CXCR4 (0.38) | MAPTL3MBTL1HPGDKDM4ECXCR4 | |
| SCHEMBL20540638 | 0.86 | MAPT (0.41) | MAPTL3MBTL1HPGDKDM4ECXCR4 | |
| SCHEMBL9222921 | 0.78 | TLR8 (0.51) | MAPTTLR8 | |
| SCHEMBL6699751 | 0.78 | CSNK2A2 (0.48) | MAPTL3MBTL1TDP1 | |
| SCHEMBL9039241 | 0.78 | SLC9A1 (0.50) | MAPTL3MBTL1HPGDKDM4ECXCR4 | |
| SCHEMBL27349215 | 0.78 | MAPT (0.39) | MAPTL3MBTL1HPGDKDM4ECXCR4 | |
| SCHEMBL169024 | 0.77 | TLR8 (0.53) | MAPTTP53ALDH1A1HTTTLR8 | |
| Hydrochloric Acid SCHEMBL30091734 | 0.77 | TLR8 (0.50) | MAPTTLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113357-A1 | Muscarinic agonists | ANDERSON CARL-MAGNUS A (DK) | 2005-05-26 | — | — | US | claimed |
| CN-1439002-A | Muscarinic agonists | ACADIA PHARM INC (US) | 2003-08-27 | — | — | CN | claimed |
| EP-1278741-A1 | MUSCARINIC AGONISTS | Acadia Pharmaceuticals Inc. (US) | 2003-01-29 | — | — | EP | claimed |
| US-20020037886-A1 | Muscarinic agonists | ACADIA PHARMACEUTICALS INC. | 2002-03-28 | — | — | US | claimed |
| WO-2001083472-A1 | MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS, INC. (US) | 2001-11-08 | — | — | WO | claimed |
| CN-101016296-A | Muscarinic agonists | ACADIA PHARM INC (US) | 2007-08-15 | — | — | CN | disclosed |
| US-20070155795-A1 | MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-7238713-B2 | Muscarinic agonists | ACADIA PHARMACEUTICALS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| CN-1814596-A | Muscarinic agonists | ARCADIA PHARMACEUTICALS INC (US) | 2006-08-09 | — | — | CN | disclosed |
| CN-1249051-C | Muscarinic agonists | ACADIA PHARM INC (US) | 2006-04-05 | — | — | CN | disclosed |
| EP-1535912-A1 | Muscarinic agonists | Arcadia Pharmaceuticals Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20050113357-A1 | Muscarinic agonists | ANDERSON CARL-MAGNUS A (DK) | 2005-05-26 | — | — | US | disclosed |
| EP-1278741-B1 | MUSCARINIC AGONISTS | ACADIA PHARM INC (US) | 2005-03-02 | — | — | EP | disclosed |
| US-6627645-B2 | Cholinergic agents | ACADIA PHARMACEUTICALS, INC. | 2003-09-30 | — | — | US | disclosed |
| CN-1439002-A | Muscarinic agonists | ACADIA PHARM INC (US) | 2003-08-27 | — | — | CN | disclosed |
| EP-1278741-A1 | MUSCARINIC AGONISTS | Acadia Pharmaceuticals Inc. (US) | 2003-01-29 | — | — | EP | disclosed |
| US-20020037886-A1 | Muscarinic agonists | ACADIA PHARMACEUTICALS INC. | 2002-03-28 | — | — | US | disclosed |
| WO-2001083472-A1 | MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS, INC. (US) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037886-A1 | Muscarinic agonists | CHRM2, CHRM1, CHRM4 | MAPT 1699/4885L3MBTL1 940/4885HPGD 2043/4885 |
| US-20070155795-A1 | MUSCARINIC AGONISTS | CHRM2, CHRM1, CHRM4 | MAPT 1699/4885L3MBTL1 940/4885HPGD 2043/4885 |
| US-20050113357-A1 | Muscarinic agonists | CHRM2, CHRM1, CHRM4 | MAPT 1699/4885L3MBTL1 940/4885HPGD 2043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.